Please login to the form below

Not currently logged in
Email:
Password:

oral GLP-1 drug

This page shows the latest oral GLP-1 drug news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk set to acquire Emisphere Technology for $1.8bn

Novo Nordisk set to acquire Emisphere Technology for $1.8bn

Novo won US Food and Drug Administration (FDA) approval for Rybelsus in September 2019, when it became the first oral alternative to injectable GLP-1 agonists. ... The two companies first teamed up in 2007 when Novo signed an initial licence agreement

Latest news

  • Lilly’s Trulicity scores CV reduction indication in the US Lilly’s Trulicity scores CV reduction indication in the US

    The new MACE approval could help Lilly in its fight for market share with other GLP-1 agonists, including Novo Nordisk’s once-weekly drug Ozempic (semaglutide). ... Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto

  • Novo Nordisk preps for speedy oral GLP-1 drug filing Novo Nordisk preps for speedy oral GLP-1 drug filing

    Despite that competition Novo’s older GLP-1 drug Victoza (liraglutide) – given as a daily injection – held up remarkably well in 2018, with sales up 5% to 24.3bn krone, while ... Oral semaglutide is seen as critical to Novo’s hopes of maintaining

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    market. Some peptides - such as transplant rejection drug cyclosporine and diuretic hormone desmopressin acetate - are simple enough to be amenable to standard oral formulation technologies and so have been available for ... Oramed - whose technology

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....